STI Stock Trade Intelligence
EYE

NOVA EYE MEDICAL LIMITED

Health Care · ASX:EYE
$0.1600
0.00%
Market cap
$46M
Turnover
$43,665
Last price
$0.1600
Day change
0.00%
Announcements
7
Range, past year
Open 0.130 · Low 0.100 · Now 0.160 · High 0.205
Open EYE in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

EYE momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
56/100
Wyckoff phase
Accumulation28d
Trend stage
Emerging
1 Day
+0.0%
1 Week
+10.3%
1 Month
+23.1%
1 Year
+23.1%
RSI
65
Avg daily range
4.7%

NOVA EYE MEDICAL LIMITED scores 56 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.

On the Wyckoff cycle it sits in Accumulation, where it has been for 28 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads low.

What stands out
  • Volume 1.5× 60-day avg
  • RSI in healthy zone (65)
  • Early discovery signal (70)
Points to watch
  • Thin liquidity
EYE appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

EYE announcements

Recent price-sensitive releases.
  • 2026-10-27 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-08-26 Full Year Financial Results Preliminary Final Report
  • 2026-08-26 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-07-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-05-05 EYE lifts Sales Guidance
  • 2026-04-29 Quarterly Activities/Appendix 4C Cash Flow Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.